1. Nat. Rev. Clin. Oncol. doi:10.1038/nrclinonc.2016.212
Figure 3 Cetuximab-800CW fluorescence in a patient with EGFR-positive head and neck cancer
Figure 3 | Cetuximab-800CW fluorescence in a patient with EGFR-positive head and neck cancer. a | Preoperative bright-field image of a patient with a cutaneous squamous- cell carcinoma and b | preoperative fluorescence acquisition of the same tumour 3 days after the patient received intravenous cetuximab-800CW (50 mg) (NCT ). The image was acquired using an open-field fluorescence imaging device (Luna; Novadaq, Ontario, Canada). c | A bright-field image of the deep surface of a resected cutaneous squamous-cell carcinoma tumour from a different patient taken 3 days after cetuximab-800CW infusion (50 mg). d | Open-field fluorescence images (obtained with Luna, Novadaq) of the same tumour depicted in c shows areas of positive fluorescence. Additional resected specimen was taken from a deeper location than that of the primary specimen; positive areas of fluorescence were detected on e | the superficial surface, but not on f | the deep surface of the additional resection margin. g | Haematoxylin and eosin staining of 5 μm sectioned tissue from a primary tumour resected from another patient with a cutaneous squamous-cell carcinoma tumour taken 3 days after intravenous administration of cetuximab-800CW (50 mg). The outlined areas denote presence of cancer (assessed by a board-certified pathologist). h | Fluorescence scan (Odyssey; Li-COR Biosciences, Lincoln, Nebraska, USA) of the adjacent cut section, with outlined areas displaying bright fluorescence intensity.
Zhang, R. R. et al. (2017) Beyond the margins: real-time detection of cancer using targeted fluorophores
Nat. Rev. Clin. Oncol. doi: /nrclinonc